Fig 2: Association of IER5 expression and clinicopathologic characteristics. (A) WHO grade, (B) Histological type, (C) Primary therapy outcome, (D) Age, (E) IDH status, (F) 1p/19q codeletion, and (G) EGFR status.

Fig 3: The expression level of IER5 was associated with immune infiltration in the tumor microenvironment. (A) Correlation between the relative abundances of 24 immune cells and IER5 expression levels. (B,C) Infiltration levels of Th2 cells and Tgd cells in the low- and high-IER5 expression groups. (D,E) Correlation between the relative enrichment score of Th2 cells and Tgd cells and the expression level of IER5.

Fig 4: Immunohistochemistry of IER5 expression in the glioma tissue microarray cohort and the validation of prognosis value of IER5 expression in Chinese Glioma Genome Atlas (CGGA) datasets. (A) Representative images of IER5 staining in the negative, weak, moderate, and strong expression groups. (B) Kaplan–Meier survival curves of overall survival stratified by IER5 protein expression. (C) Kaplan–Meier survival curves of disease-specific survival stratified by IER5 protein expression. (D–F) Kaplan–Meier survival curves of overall survival stratified by IER5 expression in three independent datasets of CGGA.

Fig 5: Correlation of IER5 expression and clinical prognosis in glioma patients with different clinicopathological factors. (A) Forest plots showing subgroup analyses of overall survival. (B–K) Kaplan–Meier survival subgroup analysis in patients stratified by clinical characteristics.